BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q4 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,915,691 | +1101.2% | 86,906 | +1340.5% | 0.02% | +650.0% |
| Q2 2023 | $492,474 | -96.5% | 6,033 | -96.8% | 0.00% | -96.5% |
| Q1 2023 | $13,989,637 | +172.2% | 188,565 | +204.1% | 0.06% | +185.0% |
| Q4 2022 | $5,139,803 | +351.3% | 62,015 | +1446.5% | 0.02% | +233.3% |
| Q3 2022 | $1,139,000 | -83.5% | 4,010 | -69.9% | 0.01% | -66.7% |
| Q4 2021 | $6,898,000 | +35.1% | 13,333 | +26.5% | 0.02% | +20.0% |
| Q3 2021 | $5,107,000 | +291.6% | 10,539 | +156.6% | 0.02% | +50.0% |
| Q4 2020 | $1,304,000 | -37.4% | 4,107 | -51.1% | 0.01% | -64.3% |
| Q3 2020 | $2,082,000 | +24.9% | 8,405 | -4.4% | 0.03% | -34.9% |
| Q1 2020 | $1,667,000 | -60.3% | 8,789 | -54.1% | 0.04% | +72.0% |
| Q4 2019 | $4,200,000 | +169.1% | 19,134 | +139.8% | 0.02% | +78.6% |
| Q3 2019 | $1,561,000 | -67.4% | 7,978 | -65.3% | 0.01% | -70.2% |
| Q2 2019 | $4,795,000 | +451.8% | 23,001 | +425.6% | 0.05% | +422.2% |
| Q1 2019 | $869,000 | +149.0% | 4,376 | +81.4% | 0.01% | +125.0% |
| Q4 2018 | $349,000 | -58.8% | 2,412 | -41.9% | 0.00% | -60.0% |
| Q3 2018 | $848,000 | +91.0% | 4,153 | +38.4% | 0.01% | +66.7% |
| Q2 2018 | $444,000 | -80.6% | 3,001 | -80.2% | 0.01% | -83.3% |
| Q1 2018 | $2,287,000 | +662.3% | 15,143 | +553.8% | 0.04% | +620.0% |
| Q4 2017 | $300,000 | – | 2,316 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |